Stock Market Rebounded from the Brink of A Real Sell-Off – Above the 40 (May 14, 2021)

Stock Market Commentary Last week featured yet another episode of momentary panic proceeded by a virtual “all clear” signal. In the middle of the week, the S&P 500 (SPY) broke down just as the stock market hit extremes. Subsequently, buyers stepped into the breach. As a result, the very next day, the stock market rebounded … Read more

Soliton Reveals More Details About Its Coming Product Launch

Soliton (SOLY) is a pre-launch medical device company specializing in technology for tattoo removal and cellulite reduction. The company is working on extending its RAP (Rapid Acoustic Pulse) technology to other indications. Soliton is still pre-launch, so the company had little to report for its financials in its latest earnings report. Management spent most of … Read more

Why Soliton Sold Off on Good News from the FDA

As highly anticipated, medical device maker Soliton (SOLY) announced the company received approval from the FDA for the cellulite indication of its Rapid Acoustic Pulse (“RAP”) technology. SOLY initially opened on February 1st with a 17.3% gain, but the stock ended the day with a 3.6% gain. Why did Soliton sell off after this good … Read more

How to Understand the Price Action From Stock Offerings

A stock offering is an opportunity for a publicly traded company to raise money for corporate investment, strengthening the balance sheet, and/or funding operations. Insider shareholders can also sell their shares to the public through a stock offering. Like any seller, these parties want to maximize the money generated from the stock sales. As a … Read more

Soliton Stock: Eagerly Anticipating News from the FDA

Almost two years have passed since I first wrote about the promise of Soliton for tattoo removal. Since then, the company expanded its indications to include cellulite removal. Soliton (SOLY) is currently rallying apparently in anticipation of news from the FDA on the cellulite application. Next, the coronavirus pandemic delayed plans for a 2020 launch. … Read more

Soliton Stock Tries Bottoming Ahead of Key Industry Event

Soliton Stock While the general stock market sold off in September, medical device company Soliton (SOLY) finally came alive. So far, the momentum continues into this month with Soliton’s stock closing at a 2 1/2 month high. SOLY is forming a potential bottom with a higher low and two higher highs including a breakout above … Read more

A Stock Market On Edge – Above the 40 (June 26, 2020)

Stock Market Statistics AT40 = 40.1% of stocks are trading above their respective 40-day moving averages (DMAs) (2-month low)AT200 = 20.1% of stocks are trading above their respective 200DMAs VIX = 34.7Short-term Trading Call: neutral Stock Market Commentary After a one-day respite, the damage in the stock market continued. This time, the damage was more … Read more

Soliton: How to Trade A Secondary Stock Offering

Last week, I anticipated that Soliton would announce a secondary offering of stock following the release of a successful trial of its cellulite treatment. Soliton (SOLY) delivered with after hours news of a secondary stock offering in the form of an SEC filing. So now what? The Trade Rules At the time of writing, traders … Read more

Soliton: What Awaits the Stock After News on Cellulite Trial

“The Company’s cash, cash equivalents and restricted cash on hand is sufficient to fund the Company’s operations into December 2020 but not beyond.” This quote from the May 14 earnings report from Soliton (SOLY) is tattooed in my mind as I consider the implications of the company’s recent good news on cellulite treatment. On June … Read more

Green Shoots for A Grinding and Historic Oversold Period – Above the 40 (March 20, 2020)

AT40 = 2.0% of stocks are trading above their respective 40-day moving averages (DMAs) (18th oversold day)AT200 = 2.6% of stocks are trading above their respective 200DMAs (new low for the oversold period)VIX = 66.0Short-term Trading Call: bullish Stock Market Commentary The bear market grinds on. At the time of writing, U.S. stock market futures … Read more